2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2627

Gender Differences of Concepts Important to People Living with Crohn’s Disease and Their Coverage by Commonly Used Patient-Reported Outcome Instruments: Patient’s Perspective Elevated by a Qualitative Study
Abstract Number: 1478

Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis
Abstract Number: 1315

Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis
Abstract Number: 525

Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
Abstract Number: 2272

Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease
Abstract Number: 1600

Gene Targeting of an Integrin-Mediated Signaling Adaptor Molecule, Crk-Associated Substrate Lymphocyte Type Reduced the Severity of Collagen-Induced Arthritis. Its Possible Involvement in the Pathophysiology of Rheumatoid Arthritis
Abstract Number: 2316

Generation of CD4⁺ Follicular Helper Tcells by Complement and Immune Complexes
Abstract Number: 1061

Generation of Myeloid-Derived Suppressor Cells in Vitro From Murine Bone Marrow Precursors
Abstract Number: 2274

Genes Associated with Systemic Lupus Erythematosus Show Evidence of Selection in the Gullah African American Population
Abstract Number: 520

Genetic Associations to Germinal Centre Formation in Primary Sjögren’s Syndrome
Abstract Number: 1535

Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis
Abstract Number: 995

Genetic Effects of HLA-DRB1, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study
Abstract Number: 970

Genetic Interactions Between SNP Variants in C3 Receptor Subunits in Patients with SLE
Abstract Number: 2279

Genetic Markers for Circulating Vitamin D and the Associations with Risk of Systemic Lupus Erythematosus
Abstract Number: 1218

Genetic Markers of Functional Stress Response in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].